China Vaccine Sector Steams To COVID Finish Line Despite Scandal-Ridden Past
Executive Summary
When a high-profile regulatory official in China was sentenced to 10 years in prison, at least five vaccine makers were found to have paid millions in bribes, although none were rigorously prosecuted. Three years later, as the country gears up for worldwide roll-out of its COVID-19 vaccines, many wonder if there are haunting glimmers from the past.
You may also be interested in...
One Year On: WHO Concludes Wuhan Probe; CanSino Vaccine 66% Effective
A WHO team concludes a high-profile investigation in Wuhan, where the first coronavirus cases surfaced over a year ago, while a single-dose vaccine from China's CanSino is on the way.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues.
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.